TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
Executive Summary
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
You may also be interested in...
Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
Risks of cancer and fungal infections are likely to grab a great deal of attention from the Gastrointestinal Drugs Advisory Committee when it reviews Centocor Ortho Biotech's Remicade (infliximab) for children July 21.
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
FDA's release of Centocor from a Risk Evaluation and Mitigation Strategy for Simponi could signal a reprieve from the REMS regulatory burden for other tumor necrosis factor inhibitors as well.
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
FDA's release of Centocor from a Risk Evaluation and Mitigation Strategy for Simponi could signal a reprieve from the REMS regulatory burden for other tumor necrosis factor inhibitors as well.